Innovative Cell Therapies TC BioPharm specializes in advanced allogeneic CAR-T and gamma delta T cell therapies for cancer and infectious diseases, offering a broad portfolio of cutting-edge treatments that can be attractive to biotech partners, research institutions, and healthcare providers seeking novel therapeutic solutions.
Strategic Collaborations The company's recent partnerships with Carnegie Mellon University and collaborations with infectious disease experts highlight opportunities to co-develop innovative AI-driven donor matching technologies and infectious disease treatments, creating potential sales channels for technology providers and research organizations.
Funding and Growth With recent capital injections totaling $8 million and non-dilutive grants of $250,000, TC BioPharm demonstrates a capacity for financial growth and investment in process optimization, indicating potential for future collaborations with investors, grant agencies, and biotech service providers.
$1B$10B
$1B$10B
$1M$10M
$1M$10M
$10M$25M
$10M$25MTC BioPharm uses 8 technology products and services including WordPress, Joomla, CookieFirst, and more. Explore TC BioPharm's tech stack below.
| TC BioPharm Email Formats | Percentage |
| F.Last@tcbiopharm.com | 84% |
| First.Last@tcbiopharm.com | 10% |
| Last@tcbiopharm.com | 5% |
| FirstLast@tcbiopharm.com | 1% |
Biotechnology ResearchUnited Kingdom51-200 Employees
TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.
Company Overview
Media & News
Funding & FinancialsTC BioPharm's revenue is estimated to be in the range of $250M$500M
Funding & FinancialsTC BioPharm's revenue is estimated to be in the range of $250M$500M
1-888-653-2347 
support@leadiq.com